聚合内容 The Healthcare Sales & Marketing Network
Healthcare Sales & Marketing Network NewsFeed
更新时间: 46 分钟 2 秒 前

Atlas Genetics Gains CE Approval for First Product

周一, 02/08/2016 - 13:33
Approval of Chlamydia test for marketing and sale in Europe BATH, England, February 8, 2016 -- (Healthcare Sales & Marketing Network) -- Atlas Genetics Ltd ("Atlas Genetics" or the "Company"), the ultra-rapid Point-Of-Care (POC) mol...
Diagnostics, Regulatory
Atlas Genetics, Chlamydia, io CT test

STENTYS initiates the Commercialization of the first Self-Expanding Drug-Eluting stent for the Below-The-Knee Indication

周一, 02/08/2016 - 13:28
PRINCETON, N.J. & PARIS--(Healthcare Sales & Marketing Network)--STENTYS (FR0010949404 — STNT) (Paris:STNT), a medical technology company commercializing the world's first and only Self-Apposing® coronary stent, today announces the first distribution a...
Devices, Interventional, Product Launch
STENTYS, Self-Apposing Stent, drug eluting stent

CTI BioPharma Provides Update On Investigational Agent Pacritinib

周一, 02/08/2016 - 13:21
FDA Places Partial Clinical Hold on Pacritinib IND; Currently Enrolled Patients Benefiting from Pacritinib Can Continue Receiving Pacritinib Phase 3 Clinical Trial (PERSIST-2) Evaluating Pacritinib for Patients with Myelofibrosis and Platelet Counts of ...
Biopharmaceuticals, Oncology
CTI BioPharma, Pacritinib, myelofibrosis

Prism Medical Announces Appointment of Chief Executive Officer

周六, 02/06/2016 - 15:06
TORONTO, ONTARIO--(Healthcare Sales & Marketing Network) - Prism Medical Ltd. ("Prism Medical" or the "Company") (TSX VENTURE:PM) announced today that Ross Scavuzzo, its Senior Vice President, Canada, has been appointed as Chief Executi...
Devices, Personnel
Prism Medical, ErgoSafe

Amarantus Requests Rare Pediatric Disease Designation from US FDA for MANF in the Treatment of Retinitis Pigmentosa

周五, 02/05/2016 - 13:35
SAN FRANCISCO, February 5, 2016 -- (Healthcare Sales & Marketing Network) -- Amarantus BioScience Holdings, Inc. (AMBS), a biotechnology company focused on developing products for Regenerative Medicine, Neurology and Orphan Diseases, announced that it has...
Biopharmaceuticals, Ophthalmology, FDA
Amarantus Bioscience, retinitis pigmentosa

TVA Medical Receives Additional Reimbursement in Germany for the everlinQ(TM) endoAVF System

周五, 02/05/2016 - 13:27
AUSTIN, Texas, Feb. 5, 2016 -- (Healthcare Sales & Marketing Network) -- TVA Medical, Inc., a medical device company developing innovative therapies for end-stage renal disease (ESRD), today announced that its everlinQTM endoAVF System has received NUB (G...
Devices, Interventional, Reimbursement
TVA Medical, everlinQ, endoAVF System, ESRD

Novogen Announces Changes to the Board with New Chairman and Deputy Chairman Appointed

周五, 02/05/2016 - 13:18
Incoming CEO James Garner appointed to the Board of Novogen New Chairman and Deputy Chairman appointed Composition of Board Committees changes SYDNEY, Feb. 5, 2016 -- (Healthcare Sales & Marketing Network) -- Australian-US drug discovery and deve...
Biopharmaceuticals, Oncology, Personnel
Novogen, Cantrixil, Anisina, superbenzopyrans

Phase 3 Study of BLINCYTO(R) (Blinatumomab) Met Primary Endpoint Of Overall Survival In Patients With B-Cell Precursor Acute Lymphoblastic Leukemia

周四, 02/04/2016 - 22:12
Study Stopped Early for Efficacy THOUSAND OAKS, Calif., Feb. 4, 2016 -- (Healthcare Sales & Marketing Network) -- Amgen (AMGN) today announced that the results of a prespecified interim analysis showed that the primary endpoint of improved overall surv...
Biopharmaceuticals, Oncology
Amgen, BLINCYTO, blinatumomab, immunotherapy, refractory ALL

Amgen Announces Positive Top-Line Results From Phase 3 GAUSS-3 Trial Of Repatha(R) (Evolocumab) In Statin-Intolerant Patients With High Cholesterol

周四, 02/04/2016 - 21:02
Study Meets Co-Primary Endpoints of LDL Cholesterol Reduction THOUSAND OAKS, Calif., Feb. 4, 2016 -- (Healthcare Sales & Marketing Network) -- Amgen (AMGN) today announced that the Phase 3 GAUSS-3 (Goal Achievement After Utilizing an Anti-PCSK9 Antibod...
Biopharmaceuticals
Amgen, GAUSS-3, Repatha, evolocumab, Statin Intolerant

GTCR Announces Third Partnership with Ed Fiorentino to Form TerSera(TM) Therapeutics

周四, 02/04/2016 - 20:52
Successful pharmaceutical veteran to build new company through acquisitions and organic growth CHICAGO, Feb. 4, 2016 -- (Healthcare Sales & Marketing Network) -- GTCR, a leading private equity firm, announced today that it has entered into a partnershi...
Biopharmaceuticals, Personnel, Venture Capital
GTCR, TerSera Therapeutics

Sigmoid Pharma Announces Acquisition of Freund Pharmatec Ltd.

周四, 02/04/2016 - 15:15
DUBLIN, Ireland, Feb. 04, 2016 -- (Healthcare Sales & Marketing Network) -- SIGMOID PHARMA LIMITED, a privately-owned, specialty pharmaceutical company developing innovative therapeutics for gastrointestinal and immunological diseases using its proprietary...
Biopharmaceuticals, Drug Delivery, Mergers & Acquisitions
Sigmoid Pharma, Freund Pharmatec, SmPill, Single-Multiple Pill

Cerapedics Announces Publication of Results from Pivotal IDE Clinical Trial of i-FACTOR(TM) Bone Graft in the Cervical Spine

周四, 02/04/2016 - 15:12
Results published in peer-reviewed journal Spine show peptide enhanced bone graft is safe and effective when compared to local autograft in ACDF procedures WESTMINSTER, Colo., Feb. 4, 2016 -- (Healthcare Sales & Marketing Network) -- Cerapedics, a priv...
Devices, Orthopaedic, Neurosurgery
Cerapedics, Bone Graft, orthobiologic

Medovex Receives Reimbursement for Its DenerveX Facet Joint Syndrome Treatment in Germany

周四, 02/04/2016 - 15:08
ATLANTA, GA--(Healthcare Sales & Marketing Network) - Medovex Corp. (NASDAQ: MDVX), a developer of medical technology products, today announced that the reimbursement authority in Germany has released new reimbursement payment coding for the DenerveX™ Syst...
Devices, Orthopaedic, Neurosurgery, Reimbursement
Medovex, DenerveX, Facet Joint Syndrome

GenomeDx Publishes First Study Supporting Use of Decipher Test in Prostate Biopsy

周四, 02/04/2016 - 13:39
Company's Proprietary Genomic Classifier Demonstrates Unprecedented Accuracy in Diagnostic Biopsies Study Published in Urology SAN DIEGO, Feb. 4, 2016 -- (Healthcare Sales & Marketing Network) -- GenomeDx Biosciences today announced publication of res...
Diagnostics, Oncology
GenomeDx Biosciences, Decipher Prostate, Cancer Classifier

Lion Biotechnologies Names Steven A. Fischkoff Chief Medical Officer

周四, 02/04/2016 - 13:32
NEW YORK, NY--(Healthcare Sales & Marketing Network) - Lion Biotechnologies, Inc. (LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL), today announced the appointment of Steven A. Fi...
Biopharmaceuticals, Oncology, Personnel
Lion Biotechnologies, immunotherapies

Eagle Pharmaceuticals Announces Appointment of Michael Moran as U.S. Head of Sales

周四, 02/04/2016 - 13:27
WOODCLIFF LAKE, N.J.--(Healthcare Sales & Marketing Network)--Eagle Pharmaceuticals, Inc. (“Eagle” or “the Company”) (EGRX) today announced that it has appointed Michael Moran, a seasoned sales executive in the pharmaceuticals industry, to the role of U.S....
Biopharmaceuticals, Personnel
Eagle Pharmaceuticals

CollPlant Reports Positive Final Trial Results for Vergenix(TM)STR, Indicated for the Treatment of Tendinopathy

周四, 02/04/2016 - 13:20
Clinical Success Demonstrated, with Improvement in Pain and Functionality at Three and Six-month Follow-ups NESS ZIONA, Israel, February 4, 2016 -- (Healthcare Sales & Marketing Network) -- CollPlant Ltd. (CLPT.TA), a regenerative medicine company util...
Biopharmaceuticals, Regenerative Medicine
CollPlant, rhCollagen, VergenixSTR, tendinopathy

Silk Therapeutics Raises $6 Million In Series A2 Financing

周三, 02/03/2016 - 19:34
Innovative Biotech Company Focused on Natural Silk Protein Raises $10.25 Million in Funding To Date MEDFORD, Mass., Feb. 3, 2016 -- (Healthcare Sales & Marketing Network) -- Silk Therapeutics, Inc., today announced the closing of a $6 million Series A2...
Dermatology, Venture Capital
Silk Therapeutics, silk protein solutions

TapImmune Granted Fast Track Designation by U.S. Food and Drug Administration for its Lead Vaccine TPIV 200 in the Treatment of Ovarian Cancer

周三, 02/03/2016 - 18:00
Expedites TapImmune's clinical development program for ovarian cancer Follows recent Orphan Drug Designation for TPIV 200 in the same indicatio JACKSONVILLE, Florida, February 3, 2016 -- (Healthcare Sales & Marketing Network) -- TapImmune, Inc. (TPI...
Biopharmaceuticals, Oncology, FDA
TapImmune, immunotherapy, Ovarian Cancer, cancer vaccine

BioDirection, Inc. Closes $4 Million Series B Financing

周三, 02/03/2016 - 17:57
Financing to support final stages of development program for Tbit™ (traumatic brain injury test) technology, designed to aid in diagnosis of concussions and other brain injuries in less than 90-seconds at point-of-care BOSTON, Feb. 3, 2016 -- (Healthcar...
Devices, Diagnostics, Neurology, Venture Capital
BioDirection, Tbit, traumatic brain injury

Contact us     New York    l    Miami    l    Sao Paulo     l    Mexico DF    l    London    l    Hong Kong